The 10-year agreement will see contract development and manufacturing organisation (CDMO) AMRI manufacture APIs, formulated products, analytical testing for the NIH, receiving up to $37.3m depending on how many projects are undertaken.
DMFP is part of the Blueprint Neurotherapeutics Network (BPN), and its goal is to support National Institute of Neurological Disorders and Stroke (NINDS) and its partners in the pharma industry and academia.
According to AMRI's President and CEO William Marth, the CDMO won the contract due to its “proven track record on projects with NIH.” In 2011 the company won a contract worth $43m to provide NINDS with services including in vivo metabolic testing and compound design.
“Since our initial NIH BPN award in 2011, AMRI has provided discovery chemistry services to NINDS and its private sector BPN members on 15 drug candidate programs, and two of these programs have advanced to the stage where a pre-clinical candidate has been declared, with a third candidate pending,” said Marth.
AMRI recently expanded its network through the acquisitions of Oso Biopharmaceutical and two manufacturing facilities owned by Aptuit.
However, according to an AMRI spokesperson the locations for the NIH work “has yet to be determined [it] will be based on the project we receive, the scope of the projects and the resources we utilize for the project.”